Annual Cash & Cash Equivalents
$127.97 M
-$35.06 M-21.51%
December 31, 2023
Summary
- As of February 7, 2025, MCRB annual cash & cash equivalents is $127.97 million, with the most recent change of -$35.06 million (-21.51%) on December 31, 2023.
- During the last 3 years, MCRB annual cash & cash equivalents has risen by +$11.92 million (+10.27%).
- MCRB annual cash & cash equivalents is now -28.91% below its all-time high of $180.00 million, reached on December 31, 2021.
Performance
MCRB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$66.82 M
-$4.41 M-6.19%
September 30, 2024
Summary
- As of February 7, 2025, MCRB quarterly cash and cash equivalents is $66.82 million, with the most recent change of -$4.41 million (-6.19%) on September 30, 2024.
- Over the past year, MCRB quarterly cash and cash equivalents has dropped by -$61.14 million (-47.78%).
- MCRB quarterly cash and cash equivalents is now -70.89% below its all-time high of $229.52 million, reached on June 30, 2023.
Performance
MCRB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
MCRB Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -21.5% | -47.8% |
| 3 y3 years | +10.3% | -59.0% |
| 5 y5 years | +49.1% | -59.0% |
MCRB Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -28.9% | at low | -70.9% | at low |
| 5 y | 5-year | -28.9% | +96.5% | -70.9% | +21.8% |
| alltime | all time | -28.9% | +7636.7% | -70.9% | +98.6% |
Seres Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $66.82 M(-6.2%) |
| Jun 2024 | - | $71.23 M(-35.9%) |
| Mar 2024 | - | $111.18 M(-13.1%) |
| Dec 2023 | $127.97 M(-21.5%) | $127.97 M(-24.7%) |
| Sep 2023 | - | $169.91 M(-26.0%) |
| Jun 2023 | - | $229.52 M(+142.0%) |
| Mar 2023 | - | $94.84 M(-41.8%) |
| Dec 2022 | $163.03 M(-9.4%) | $163.03 M(-20.6%) |
| Sep 2022 | - | $205.40 M(+62.0%) |
| Jun 2022 | - | $126.82 M(-17.2%) |
| Mar 2022 | - | $153.19 M(-14.9%) |
| Dec 2021 | $180.00 M(+55.1%) | $180.00 M(-20.9%) |
| Sep 2021 | - | $227.46 M(+207.4%) |
| Jun 2021 | - | $74.00 M(+11.1%) |
| Mar 2021 | - | $66.58 M(-42.6%) |
| Dec 2020 | $116.05 M(+78.2%) | $116.05 M(-44.0%) |
| Sep 2020 | - | $207.33 M(+236.9%) |
| Jun 2020 | - | $61.54 M(+12.2%) |
| Mar 2020 | - | $54.86 M(-15.8%) |
| Dec 2019 | $65.13 M | $65.13 M(+32.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $49.30 M(-51.8%) |
| Jun 2019 | - | $102.23 M(+90.7%) |
| Mar 2019 | - | $53.60 M(-37.5%) |
| Dec 2018 | $85.82 M(+137.8%) | $85.82 M(+54.0%) |
| Sep 2018 | - | $55.71 M(-3.9%) |
| Jun 2018 | - | $57.96 M(+22.8%) |
| Mar 2018 | - | $47.19 M(+30.8%) |
| Dec 2017 | $36.09 M(-33.8%) | $36.09 M(-21.6%) |
| Sep 2017 | - | $46.02 M(+36.8%) |
| Jun 2017 | - | $33.64 M(-19.7%) |
| Mar 2017 | - | $41.90 M(-23.2%) |
| Dec 2016 | $54.54 M(-26.2%) | $54.54 M(-1.9%) |
| Sep 2016 | - | $55.61 M(-7.0%) |
| Jun 2016 | - | $59.82 M(-69.0%) |
| Mar 2016 | - | $193.23 M(+161.4%) |
| Dec 2015 | $73.93 M(-35.3%) | $73.93 M(+6.1%) |
| Sep 2015 | - | $69.70 M(+91.8%) |
| Jun 2015 | - | $36.34 M(-19.3%) |
| Mar 2015 | - | $45.05 M(-60.6%) |
| Dec 2014 | $114.19 M(+6803.6%) | $114.19 M |
| Dec 2013 | $1.65 M | - |
FAQ
- What is Seres Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Seres Therapeutics?
- What is Seres Therapeutics annual cash & cash equivalents year-on-year change?
- What is Seres Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Seres Therapeutics?
- What is Seres Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Seres Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of MCRB is $127.97 M
What is the all time high annual cash & cash equivalents for Seres Therapeutics?
Seres Therapeutics all-time high annual cash & cash equivalents is $180.00 M
What is Seres Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, MCRB annual cash & cash equivalents has changed by -$35.06 M (-21.51%)
What is Seres Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of MCRB is $66.82 M
What is the all time high quarterly cash and cash equivalents for Seres Therapeutics?
Seres Therapeutics all-time high quarterly cash and cash equivalents is $229.52 M
What is Seres Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, MCRB quarterly cash and cash equivalents has changed by -$61.14 M (-47.78%)